Maplelane Capital’s Medifast MED Stock Holding History

Maplelane Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,375	Closed	-$150K	–	126
2019 Q4	$150K	Buy	1,375 +1,374	+137,400%	+$133K	﹤0.01%	120
2019 Q3	$0	Buy	+1	New	+$107	﹤0.01%	150

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Maplelane Capital's MED Position: Q1 2020 in Review

Maplelane Capital sold out of Medifast (MED) in Q1 2020, closing a stake of 1,375 shares — an estimated $150K sold.

Maplelane Capital first reported a position in MED in Q3 2019 and held it in 2 quarters. The position peaked at $150K in Q4 2019. 201 funds tracked by Wall St. Rank hold MED as of Q1 2020.

Maplelane Capital reported no remaining Medifast position as of Q1 2020 after selling out during the quarter.
Maplelane Capital sold 1,375 Medifast shares in Q1 2020, an estimated $150K.
Maplelane Capital first reported a position in Medifast in Q3 2019 and held it in 2 quarters.
Maplelane Capital's Medifast position peaked at $150K in Q4 2019.
201 funds tracked by Wall St. Rank held Medifast as of Q1 2020.

Based on Maplelane Capital's 13F filing for Q1 2020, filed 15 May 2020.